【harbinger of the seas ruling】EyePoint Pharmaceuticals (EYPT) Reports Q4 Loss, Tops Revenue Estimates
EyePoint Pharmaceuticals (EYPT) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.12. This harbinger of the seas rulingcompares to loss of $0.12 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 25%. A quarter ago, it was expected that this drug delivery technology company would post a loss of $0.14 per share when it actually produced a loss of $0.14, delivering no surprise. Over the last four quarters, the company has surpassed consensus EPS estimates two times. EyePoint Pharmaceuticals, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $8.63 million for the quarter ended December 2019, surpassing the Zacks Consensus Estimate by 12.19%. This compares to year-ago revenues of $2.44 million. The company has topped consensus revenue estimates two times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. EyePoint Pharmaceuticals shares have lost about 7.1% since the beginning of the year versus the S&P 500's decline of -3.1%. What's Next for EyePoint Pharmaceuticals? While EyePoint Pharmaceuticals has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for EyePoint Pharmaceuticals was favorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #2 (Buy) for the stock. So, the shares are expected to outperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Story continues It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.11 on $8.73 million in revenues for the coming quarter and -$0.32 on $48.32 million in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the top 40% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report EYEPOINT PHARMACEUTICALS, INC. (EYPT) : Free Stock Analysis Report To read this article on Zacks.com click here. View comments
相关推荐
-
Donaldson (DCI) Q1 Earnings & Sales Top Estimates, Decline Y/Y
-
Canada energy firms fret as Ottawa labors over promised aid package
-
Trump threatens to deploy U.S. military to quell riots across the country
-
Microsoft (MSFT) Is a Bargain Stock You Can Buy Today
-
Glencore commits to net zero emissions by 2050
-
One Metric To Rule Them All: Ground Rents Income Fund PLC (LON:GRIO)
- 最近发表
-
- EXCLUSIVE: Frédéric Arnault Gears Up for CEO Role at Tag Heuer
- Lam Research unveils improved tool to make 3-D chips for phones, devices
- Moderna to supply 100 to 125 mln COVID-19 vaccine doses globally in first quarter
- Mixed Near-Term Outlook for Agriculture Operations Industry
- S&P 500 Preview – Security Software and Retail Headline Tuesday’s Earnings
- Insights on the Surgical Sealant/Tissue Patch Global Market to 2025 - Key Drivers and Restraints
- Square Inc (SQ) President, CEO & Chairman Jack Dorsey Sold $20.9 million of Shares
- Acadia Pharmaceuticals (ACAD) Reports Q3 Loss, Tops Revenue Estimates
- Where Do Hedge Funds Stand On FS Bancorp, Inc. (FSBW)?
- Can You Imagine How Eagle Nice (International) Holdings's (HKG:2368) Shareholders Feel About The 96% Share Price Increase?
- 随机阅读
-
- FITB ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of June 8, 2020 in the Class Action Filed on Behalf of Fifth Third Bancorp Limited Shareholders
- IRS offers new relief options to help with tax bills during coronavirus pandemic
- Sanoma Oyj: Managers' Transactions
- MORNING BID-Between stimulus euphoria and virus dejection
- Wisconsin Father Hits 500,000 Push-up Milestone on the Path to Break World Record
- Does ICC Holdings, Inc.'s (NASDAQ:ICCH) CEO Pay Reflect Performance?
- How to Time the Markets Like an Investing Pro - April 01, 2020
- AGI or RGLD: Which Is the Better Value Stock Right Now?
- The Global Virtualization in Industrial Automation Market is expected to grow by $ 216.39 mn during 2020-2024 progressing at a CAGR of 4% during the forecast period
- TREASURIES-U.S. 10-year yield stays below 1% as coronavirus fears persist
- Before You Buy Youngevity International, Inc. (NASDAQ:YGYI), Consider Its Volatility
- WRAPUP 1-Standard U.S. economic weapons may be inadequate for coronavirus crisis
- Were Hedge Funds Right About Automatic Data Processing (ADP)?
- Baker Hughes Snaps Up Compact Carbon Capture For Energy Transition Path
- Dow Inc. (DOW) Gains But Lags Market: What You Should Know
- Gaming platform Roblox acquires Imbellus assets ahead of IPO
- Should You Like Vidrala, S.A.’s (BME:VID) High Return On Capital Employed?
- Understated Factors To Consider Before Investing In Esquire Financial Holdings, Inc. (NASDAQ:ESQ)
- TAL EDUCATION INVESTOR ALERT: National Litigation Firm Labaton Sucharow Announces Investigation of TAL Education Group (TAL) and Strongly Encourages Stock, Options, Derivative Investors with Losses to Contact the Firm
- Were Hedge Funds Right About Chipotle Mexican Grill (CMG)?
- 搜索
-
- 友情链接
-
- Exxon CEO sticks to spending targets as oil prices tumble
- DCP Midstream to Participate in Investor Conferences
- After Facebook deal, Reliance Jio rakes in $747 million from PE giant Silver Lake
- CANADA STOCKS-TSX plunges as coronavirus rout rages
- AstraZeneca's COVID-19 Vaccine Trial Delays May Worsen As FDA Widens Investigation
- This Day In Market History: Buffett's $3B GE Bet
- PharmaCielo Shareholder Alert: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In PharmaCielo Ltd. To Contact The Firm
- Sientra to Present at the William Blair 40th Annual Growth Stock Conference
- Is Cobre (ASX:CBE) In A Good Position To Deliver On Growth Plans?
- National CineMedia (NCMI) Jumps: Stock Rises 10.6%